EICHORPublic-registry site landscape for NCT05027997, “Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm”, a Blepharospasm study sponsored by Addex Pharma S.A.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05027997 (registry record) |
| Study title | Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm |
| Official title | Exploratory Phase 2a Randomized, Double-blind, Placebo-controlled Study of Dipraglurant (ADX48621) Immediate Release Tablets in Patients With Blepharospasm |
| Sponsor | Addex Pharma S.A. |
| Condition(s) | Blepharospasm; Dystonia |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05027997.
Eichor generates a preliminary site-risk snapshot for NCT05027997 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Blepharospasm studies · Weekly briefs
